Can we all survive propofol?
In this issue of Anaesthesia and Intensive Care, Fry, Fry and Castanelli report the results of their long-awaited followup survey on substance abuse by anaesthetists in Australia and New Zealand 1 . This is the third retrospective survey on substance abuse to have been published in this journal. In 1993, Weeks et al reported addiction in Australian anaesthesia trainees from 1981 to 1991 2 . It prompted JG Roberts in his accompanying editorial entitled 'The Kraken Wakes' to declare "the scourge is upon us" and he noted the phrase "only in America" was no longer valid, as substance abuse had reached our antipodean haven 3 . The subsequent survey published by Fry in 2005 differed in that it had asked directors of public hospital anaesthesia departments across Australia and New Zealand to retrospectively report substance misuse by trainees and fellows 4 . It was again accompanied by an editorial, this time by L Roberts who opined "so little and so far" 5 . She noted substantial gains in the area of anaesthetists' health and welfare, but presciently expressed reservations that targeting only training departments excluded the private sector where detection and management of substance abuse posed potentially greater logistical challenges.
With the publication of the latest report, the anaesthesia community in Australia and New Zealand now has approximately 30 years of data on which to reflect 1, 2, 4 . Analysis of the most recent survey confirms that despite increasing awareness and education, the incidence of substance abuse remains similar, at about 1.2 cases per 1000 anaesthetist years. What has changed dramatically is the number of reported cases of propofol abuse. For the first time since 1981, propofol has overtaken fentanyl as the preferred substance of abuse amongst substance-abusing anaesthetists. Propofol was implicated in 41% of the total cases reported by the respondents to the survey, which is double the incidence reported in 2005 and seven times the incidence of induction agent abuse in the original 1993 survey 2, 4 . This should be of immense concern to all anaesthetists, because propofol, more than any other of the abused substances in these surveys, has the potential to result in death. Fry et al have reported a mortality rate from propofol of a sobering 45%. This is the highest published to date and while the methodology may be imperfect due to the retrospective and second-hand reporting nature of the survey, it may reflect our regional reduction in access to opiates and the rising incidence of propofol abuse and perhaps addiction.
Awareness of propofol as a substance of abuse worldwide has grown since the first publication in 1991 of a case report detailing an American anaesthetist injecting himself with 100 mg up to 15 times per day 6 . The accompanying editorial by Ward reasoned that propofol access should be restricted "because it clearly is a mood-altering drug" 7 . Fourteen years later, he continued his campaign to regulate propofol in the USA, commenting that "rules rarely ever stop the 'truly motivated' but they can at times deter the 'simply inquisitive'" 8 .
There are inconsistencies regarding the storage and availability of propofol from country to country. In some regions it is unaccompanied by the regulations that govern other drugs of addiction including benzodiazepines and opioids. In others, regulatory authorities have stringently designated it as a drug of addiction and abuse 9 . Therein lies perhaps much of its appeal: a familiar and short-acting drug with minimal sideeffects when administered in small doses, little or no pharmacy accounting and often widely available in clinical areas, making detection unlikely until an error of judgement or dosing results in discovery, coma or death. Reluctance to restrict propofol access stems from concerns that in an emergency situation such as the treatment of laryngospasm or a category 1 caesarean delivery, secure storage will be inconvenient at best and, at worst, potentially life-threatening. Nevertheless, despite the inconvenience, many institutions worldwide regulate propofol storage, dispensation and disposal. As yet no case reports of patient harm have emerged.
It remains contentious as to when (or perhaps even if) anaesthetists should return to the operating theatre to administer the substance to which they have been previously addicted. Only 28% of propofol abusers in this survey returned to work. Addiction medicine specialists are qualified to advise on this complex issue and take many factors into account, including family history of substance abuse and the presence of a coexisting psychiatric disorder. For example, substantial differences exist between the once-only substance abuser and the habitual user, including receptor down-regulation and the likelihood of relapse. However, both represent serious boundary violations that warrant full investigation and assessment by an addiction medicine specialist prior to a conditional return to patient care. With this in mind, we support an approach that assesses suitability to return to work in anaesthesia on an individual basis, rather than enforcing a blanket policy of exclusion from the high-risk theatre environment that has been advocated by others 10 . Only 11% of reported cases in the latest survey were managed as inpatients at presentation. This contravenes the prevailing wisdom that initial admission to a residential program for a variable time period, ranging from weeks to months, is more likely to achieve a sustained recovery and to reduce the likelihood of relapse [11] [12] [13] . This finding also does little to allay the suspicion that some substance abusers may be returning to work prematurely.
Addiction medicine has made considerable advances in the epoch since 1981. Sustained-release antagonists appear to show great promise in reducing craving, relapse and death during relapse in alcohol, opiate and benzodiazepine abusers 14, 15 ; however, no sustained-release antagonist is currently available for propofol. Relapses with propofol abuse are common and carry a high risk of death. In one study, 50% of propofol-abusing anaesthetists who returned to work in anaesthesia after rehabilitation subsequently relapsed 16 . Successful detoxification and rehabilitation do not necessarily translate into sustained, lifelong remission and relapses are reported well beyond the magical five-year mark when most surveillance periods terminate. Data from the United States suggest that 40% of substance-abusing trainees will relapse at least once during a 30-year career 17 . The high relapse rate emphasises the need for ongoing treatment, monitoring and surveillance that we believe should span the entire career of a rehabilitated anaesthetist.
When the dimension of private practice is superimposed onto the issue of propofol addiction, further troubling questions arise. Fry et al emphasise that they surveyed only teaching hospital departments. As about one-fifth of anaesthetists in our region are in full-time practice with no teaching hospital affiliation, the substance abuse rates reported by Fry et al are almost certainly an underestimate. As L Roberts predicted over ten years ago, this burgeoning community of full-time private practitioners are potentially being missed as progress is made towards educating anaesthetists about their own wellbeing. Trainees appear to be the primary beneficiaries of the emerging culture of welfare officers in anaesthesia 18 . As yet, there are no formal reports of their existence in private practice groups. This in no way negates the considerable care and concern that private practitioners extend toward their colleagues. Rather, it leaves those in full-time private practice without a comparable and accessible framework to educate and assist with welfare matters. We encourage private practices to appoint suitable anaesthetists into formal peer support roles to educate their practice employees and colleagues about substance abuse and self-care. The health of their practice members should be considered as the foundation of their core business, the provision of quality anaesthesia.
Regulatory authorities and addiction medicine specialists return rehabilitated substance abusing anaesthetists to practice intending to prevent patient exposure to unacceptable risk. After harmful failures of supervision of addicted anaesthesia providers both here and overseas, tools to assist fellows to return to private practice in a strictly supervised capacity are still lacking and sorely needed [19] [20] [21] . When an anaesthetist administers anaesthesia under the supervision of another anaesthetist, only one can bill for the provision of anaesthesia services for any specific item for that patient. The financial implications pose a significant barrier to an anaesthetist requiring supervision during a return to a safe practice. For the practitioner in a group, it requires tremendous goodwill from colleagues to agree to supervise and even more to forgo earnings in order to strictly supervise. For the practitioner in solo private practice, it may be impossible to obtain adequate supervision, rendering the resumption of a career in private practice unattainable. Consequently, it seems prudent to mandate at least an initial period in a designated anaesthesia department where resources and support are more readily available. In addition, the creation of a private practice benevolent fund might alleviate some of the financial distress that accompanies the psychological, emotional and social distress of substance abuse.
For the first time since 1981, the incidence of substance abuse in female anaesthetists exceeds males. Does this represent the increased feminisation of the workforce or further illuminate the picture that female doctors are now experiencing higher distress, developing more minor psychiatric disorders, more depression and anxiety and more suicidal ideation than their male counterparts 22 ? The presence of Axis I and II disorders are known to be major risk factors for the development of addiction 13 and we will watch with interest whether these findings are borne out by other researchers.
The American Society of Anesthesiologists Task Force on Chemical Dependency provides a course on drug abuse and addiction for anesthesiology trainees, which includes learning points on re-entry criteria and a sample re-entry agreement. It has also developed a document for anesthesiology trainees and their families on chemical dependence 23 . The inclusion of a mandatory substance abuse module for both fellows and trainees in Australia and New Zealand is overdue in our opinion.
It was with great disappointment we read that the response rate for this survey was only 57% compared with 78% for both previous surveys. The rate of substance abuse does not appear to have diminished in the intervening years and departmental directors shoulder much of the burden of managing this challenging problem in the workplace. This research provides them with vital information and we hope it receives due attention from respondents and nonrespondents alike. We commend Fry et al and anticipate that their next survey in ten years' time will be received by directors in both private and public practice who understand its importance more widely and allocate appropriate resources to completing it. This is a topic that affects us profoundly, whether directly or indirectly, and collecting data is the first step in understanding and managing the problem.
Thirty years on, we now know that about 10% of anaesthetists will have an episode of substance abuse in their lifetime (consistent with the prevalence of substance abuse disorders in the general population) 13 . Propofol abuse will kill talented but troubled individuals and its increasing incidence requires urgent attention in addition to the current measures to prevent abuse of other drugs. This survey highlights that Australian and New Zealand anaesthetists lack a clear, unified approach to the substance-abusing anaesthetist and we join Fry et al in their call for standardised treatment protocols. Can we survive unregulated and unrestricted propofol? Coronial inquests around the region suggest that increasingly, some of us will not 24, 25 .
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